Updated on 26 March 2013
Dr Kiran Mazumder Shaw, chairman and managing director, Biocon pointed out "The purpose of this partnership is to accelerate the progress of this novel molecule through global clinical trials under guidance from a well entrenched global player, in order to meet the unmet need of diabetic patients across the world. Biocon's Oral insulin will possibly be the first oral insulin of the world to hit the market. We are confident that with BMS expertise available to Biocon, we will be able to take oral insulin forward on its development pathway much faster, we look forward to working closely with BMS to shape our dream into reality."
Panacea Biotec, an Indian firm whose three cardinal business principles have been focus on innovation, brand building and collaboration, collaborated with Osmotica Pharmaceutical, a drug delivery specialized company and brings to the collaboration an immense expertise on the regulatory and commercialization aspects of complex drug delivery based generics, in September 2012. This strategic alliance is for the research, development and commercialization of drug delivery based, high-barrier-to-entry generic and branded pharmaceutical products in US and key strategic markets across the globe with Osmotica. The collaboration is designed to build upon each company's highly complementary strengths and quality assets.
Panacea Biotec would lead product identification, research, development and manufacturing while Osmotica would lead product registration, legal matters, marketing, sales and distribution.
Dr Rajesh Jain, joint managing director, Panacea informed, "The collaboration products are expected to be sold under an Osmotica and Panacea Biotec label. This collaboration is based on a 50:50 risk, investment and profit sharing by both companies and starts with a portfolio of 18 products across a broad range of therapeutic categories, with a provision to add new products by the Joint Steering Committee represented by both Osmotica and Panacea Biotec."
Panacea Biotec has received a research fee from Osmotica on signing and milestone payments over the past months. Moving forward, Panacea Biotec will receive agreed amounts of milestone payments representative of 50 percent share of development costs from Osmotica on achievement of development milestones. For every new product added to the collaboration and for each new market thereof, Panacea Biotec shall receive a fixed License Fee besides receiving the 50 percent development costs. Post commercialization of the products in USA and other markets as may be added from time to time, both Panacea Biotec and Osmotica shall share the profits equally.
Panacea in the same year collaborated with Kreamers Urban, a specialty generic business subsidiary of UCB, with an exclusive focus on pharmaceutical products that have a "high-barrier-to-entry". Panacea Biotec announced the strategic alliance with Kremers Urban for 11 High Barrier to Entry Generic products in the US market representing an opportunity of $ 4 Billion at the innovator sales level in US.
The first product in this portfolio to reach the market was Tacrolimus capsules, launched in US in Nov 2012. Panacea Biotec was granted approval of the product from USFDA in Sep 2012. This would be followed by a series of high barrier to entry generic product launches that are being developed by Panacea Biotec.